Financial Security Advisor Inc. Takes $900,000 Position in Stryker Corporation $SYK

Financial Security Advisor Inc. bought a new stake in Stryker Corporation (NYSE:SYK) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 2,555 shares of the medical technology company’s stock, valued at approximately $900,000.

Other large investors also recently made changes to their positions in the company. United Financial Planning Group LLC acquired a new position in shares of Stryker in the 3rd quarter valued at about $27,000. Strive Asset Management LLC acquired a new position in shares of Stryker in the 3rd quarter valued at about $30,000. CGC Financial Services LLC acquired a new position in shares of Stryker in the 4th quarter valued at about $29,000. ANTIPODES PARTNERS Ltd acquired a new position in shares of Stryker in the 3rd quarter valued at about $34,000. Finally, Copia Wealth Management increased its holdings in shares of Stryker by 181.6% in the 3rd quarter. Copia Wealth Management now owns 107 shares of the medical technology company’s stock valued at $40,000 after purchasing an additional 69 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Trading Up 0.4%

NYSE:SYK opened at $306.74 on Friday. The stock’s 50 day moving average price is $329.68 and its 200 day moving average price is $351.73. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $404.87. The company has a market capitalization of $117.59 billion, a P/E ratio of 35.50, a P/E/G ratio of 1.92 and a beta of 0.80. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The company had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period in the previous year, the company earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, research analysts forecast that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio is presently 40.74%.

Insider Transactions at Stryker

In other Stryker news, VP M Kathryn Fink sold 5,220 shares of the stock in a transaction on Monday, May 11th. The stock was sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the completion of the transaction, the vice president directly owned 13,137 shares in the company, valued at $3,728,937.45. This represents a 28.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 4.60% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms recently commented on SYK. Sanford C. Bernstein set a $410.00 price objective on Stryker in a report on Friday, May 1st. The Goldman Sachs Group restated a “neutral” rating and issued a $361.00 price objective on shares of Stryker in a report on Friday, May 1st. UBS Group dropped their price objective on Stryker from $400.00 to $380.00 and set a “neutral” rating on the stock in a report on Tuesday, March 17th. JPMorgan Chase & Co. dropped their price objective on Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Finally, Truist Financial restated a “hold” rating and issued a $330.00 price objective (down from $380.00) on shares of Stryker in a report on Monday, May 4th. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $395.48.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.